Elicio Therapeutics (ELTX) EPS (Basic) Growth (1y) (2021 - 2026)
Elicio Therapeutics (ELTX) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | -16.29% |
| 10 | Elicio Therapeutics | 59.32 Mn | 35.82 Mn | - | 11.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.54% |
| Mar 31, 2026 | -44.04% |
| Dec 31, 2025 | 43.00% |
| Sep 30, 2025 | -45.18% |
| Jun 30, 2025 | 37.94% |
| Mar 31, 2025 | 18.88% |
| Dec 31, 2024 | 45.57% |
| Sep 30, 2024 | 67.79% |
| Jun 30, 2024 | 53.97% |
| Mar 31, 2024 | 61.79% |
| Dec 31, 2023 | 4.10% |
| Sep 30, 2023 | 30.69% |
| Jun 30, 2023 | -48.19% |
| Mar 31, 2023 | 45.27% |
| Dec 31, 2022 | -139.75% |
| Sep 30, 2022 | 75.32% |
| Jun 30, 2022 | 83.67% |
| Mar 31, 2022 | 42.65% |
| Dec 31, 2021 | 157.42% |
| Sep 30, 2021 | -73.44% |